RxDoctor Payments Data

Caridad Hollingshead, APRN

Family · Tampa, FLNPI 1013662113

Payments from drug & device makers

$859in general payments, 2019–2025

Across 17 payments — averaging $50.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$288
  • Lilly USA, LLC$233
  • AstraZeneca$149
  • Bayer$67
  • Otsuka America Pharmaceutical, Inc.$57
  • Boston Scientific$24
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$6,095
Medicare patients
19
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol139$136,890
OzempicSemaglutide99$111,362
TrulicityDulaglutide22$40,996
JardianceEmpagliflozin33$38,483
EliquisApixaban31$30,705
JanuviaSitagliptin Phosphate21$28,080
LinzessLinaclotide22$18,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,840
SymbicortBudesonide/Formoterol Fumarate43$15,736
RybelsusSemaglutide13$14,199
Spiriva RespimatTiotropium Bromide12$10,807
Omega-3 Acid Ethyl Esters64$6,862
Clonidine35$4,937
Albuterol Sulfate HfaAlbuterol Sulfate136$4,773
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$149$152,626182 claims
Novo NordiskOzempic, Rybelsus$288$125,561112 claims
Lilly USA, LLCTrulicity$233$40,99622 claims
PfizerEliquis$18$30,70531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →